For use by biological product manufacturers to report biological product deviations (BPD) that may affect the safety, purity, or potency of a distributed product in accordance with 21 CFR, Part 600.14 or 606.171. Also for use by Human Cells, Tissues and Cellular and Tissue-Based Product (HCT/P) manu
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/B5YqfmS
No comments:
Post a Comment